Medexus Pharmaceuticals (MDP) investor relations material

Strategic focus and business model

• Specializes in orphan drugs and rare disease pharmaceuticals, targeting North America with a scalable infrastructure and salesforce.

• Drives growth through market performance, new product launches, and targeted development, with a focus on commercial and late-stage products.

• Pursues value creation via product licensing, acquisitions, and pipeline expansion, especially in Allo-HSCT.

Product portfolio and market position

• Portfolio includes 14 brands, with leading products in hematology, hemato-oncology, rheumatology, and allergy.

• GRAFAPEX (treosulfan) is the first and only FDA-approved conditioning regimen for allo-HSCT, with $11.6M FY2026 product-level net revenue and strong growth potential.

• Trecondyv (treosulfan) launched in Canada in 2021, showing rapid growth and positive clinical outcomes compared to busulfan-based regimens.

• IXINITY (hemophilia B) holds global rights, with a concentrated US market and patent protection through 2028.

• Rasuvo/Metoject leads the US methotrexate autoinjector market, with exclusive or advantaged payer status.

Financial performance and capital structure

• FY2026 net revenue reached $99.3M, with 75% generated in the US and a 5-year CAGR of 4%.

• Adjusted EBITDA for FY2026 was $16.5M, with operating cash flow of $18.9M and net income of $0.5M.

• Enterprise value as of August 2026 was $141.3M, with $120.4M equity market capitalization and $20.9M net debt.

• Credit facility includes $21M term loan, $5M revolving loan, and $10M delayed draw for business development.